Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Investigating the Effects of MLL5 on Primitive Cells in Hematopoietic Malignancies

FY 2009-10

Summary
Although cancers of the blood, or leukemias, have been recognised and studied for many decades, current treatments are associated with severe toxicity and are often ineffective in patients. Thus, there is a strong need to better understand the way in which leukemia arises and differs from normal blood production so that new, less-toxic treatments can be developed. I intend to investigate the recently-discovered gene mixed lineage leukemia 5 (MLL5) and its role in the regulation of cells that produce primitive blood. The loss of this gene has been recently reported to result in profound disturbances in maturation and function of blood cells, from the most primitive (stem cells) to mature cells, suggesting that MLL5 may be involved in orchestrating the expression of a huge repertoire of genes, which may have widespread effects on the growth of primitive cells. Studying the ways in which MLL5 acts and its effects on cells may reveal potential targets for drug therapy. In addition, I will investigate ways to influence MLL5 expression and modulate its effects on other cells. To perform these studies, I will take advantage of powerful mouse models where MLL5 or parts of the gene are deleted, which will allow identification of the domain(s) responsible for the responses of both stem cells and mature cells to MLL5. In addition, I will investigate the effects of powerful drugs, including those that can alter epigenetic modifications or cause cells to undergo maturation, on MLL5 cells and their composite domains, as interrupting or modulating MLL5 function might be a powerful new approach to making leukemic cells more sensitive to drug treatments. These results will set the stage for more detailed investigations of the proteins that influence and interact with key MLL5 domains. Furthermore, knowledge gained from these studies will be invaluable in the search for drugs that can interfere with or enhance MLL5 activity, helping to develop improved treatments against leukemia.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
201565
Name
Lai Courteney
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Investigating the Effects of MLL5 on Primitive Cells in Hematopoietic Malignancies
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Signaling; Cellular Differentiation; Cloning; Epigenetics; Gene Regulation/Expression; Hematopoetic Stem Cells; Hematopoiesis; Leukemia/Cancer; Mixed Lineage Leukemia 5; Molecular Biology
Abstract
Although cancers of the blood, or leukemias, have been recognised and studied for many decades, current treatments are associated with severe toxicity and are often ineffective in patients. Thus, there is a strong need to better understand the way in which leukemia arises and differs from normal blood production so that new, less-toxic treatments can be developed. I intend to investigate the recently-discovered gene mixed lineage leukemia 5 (MLL5) and its role in the regulation of cells that produce primitive blood. The loss of this gene has been recently reported to result in profound disturbances in maturation and function of blood cells, from the most primitive (stem cells) to mature cells, suggesting that MLL5 may be involved in orchestrating the expression of a huge repertoire of genes, which may have widespread effects on the growth of primitive cells. Studying the ways in which MLL5 acts and its effects on cells may reveal potential targets for drug therapy. In addition, I will investigate ways to influence MLL5 expression and modulate its effects on other cells. To perform these studies, I will take advantage of powerful mouse models where MLL5 or parts of the gene are deleted, which will allow identification of the domain(s) responsible for the responses of both stem cells and mature cells to MLL5. In addition, I will investigate the effects of powerful drugs, including those that can alter epigenetic modifications or cause cells to undergo maturation, on MLL5 cells and their composite domains, as interrupting or modulating MLL5 function might be a powerful new approach to making leukemic cells more sensitive to drug treatments. These results will set the stage for more detailed investigations of the proteins that influence and interact with key MLL5 domains. Furthermore, knowledge gained from these studies will be invaluable in the search for drugs that can interfere with or enhance MLL5 activity, helping to develop improved treatments against leukemia.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lai, Courteney
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~